EGFR and non-small cell lung carcinoma: In the ENSURE study, which examined 217 patients, 61% of whom were women, with stage IIIB/IV EGFR-mutated NSCLC, comparing erlotinib to a cisplatin doublet, the median PFS was 11 months in the erlotinib group versus 5.5 months in the chemotherapy group [54].